APA (7th ed.) Citation

CM, C., A, N., M, G., S, F., AKA, A., R, K., . . . MM, P. (2025). Multiple TET2 mutations confer additional survival benefit in both myelodysplastic and myeloproliferative chronic myelomonocytic leukemia subtypes. Leukemia, 39(8), 2030. https://doi.org/10.1038/s41375-025-02648-w

Chicago Style (17th ed.) Citation

CM, Csizmar, et al. "Multiple TET2 Mutations Confer Additional Survival Benefit in Both Myelodysplastic and Myeloproliferative Chronic Myelomonocytic Leukemia Subtypes." Leukemia 39, no. 8 (2025): 2030. https://doi.org/10.1038/s41375-025-02648-w.

MLA (9th ed.) Citation

CM, Csizmar, et al. "Multiple TET2 Mutations Confer Additional Survival Benefit in Both Myelodysplastic and Myeloproliferative Chronic Myelomonocytic Leukemia Subtypes." Leukemia, vol. 39, no. 8, 2025, p. 2030, https://doi.org/10.1038/s41375-025-02648-w.